GCM
BSX icon

Gladius Capital Management’s Boston Scientific BSX Stock Holding History

Gladius Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-165
Closed -$7K – 143
2021
Q1 		$7K Sell
165
-1,422
-90% -$53.8K ﹤0.01% 167
2020
Q4 		$58K Buy
1,587
+509
+47% +$18.3K ﹤0.01% 163
2020
Q3 		$42K Buy
+1,078
New +$41.5K ﹤0.01% 177

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

Gladius Capital Management's BSX Position: Q2 2021 in Review

Gladius Capital Management sold out of Boston Scientific (BSX) in Q2 2021, closing a stake of 165 shares — an estimated $7K sold.

Gladius Capital Management first reported a position in BSX in Q3 2020 and held it in 3 quarters. The position peaked at $58K in Q4 2020. 867 funds tracked by Wall St. Rank hold BSX as of Q2 2021.

  • Gladius Capital Management reported no remaining Boston Scientific position as of Q2 2021 after selling out during the quarter.
  • Gladius Capital Management sold 165 Boston Scientific shares in Q2 2021, an estimated $7K.
  • Gladius Capital Management first reported a position in Boston Scientific in Q3 2020 and held it in 3 quarters.
  • Gladius Capital Management's Boston Scientific position peaked at $58K in Q4 2020.
  • 867 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2021.

Based on Gladius Capital Management's 13F filing for Q2 2021, filed 6 Aug 2021.